<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Satralizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Satralizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Satralizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="129318" href="/d/html/129318.html" rel="external">see "Satralizumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54809547"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Enspryng</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54927893"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Enspryng</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54749987"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interleukin-6 Receptor Antagonist;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54779730"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer all live or live-attenuated vaccines at least 4 weeks prior, and non-live vaccines at least 2 weeks prior to initiation of satralizumab. Assess patients for presence of any active infection; delay treatment until active infection is resolved. Screen for hepatitis B (hepatitis B surface antigen [HBsAg] and hepatitis B core antibody [HBcAb]) prior to initiation; do not administer to patients with active hepatitis B. Evaluate for tuberculosis (TB) infection/disease (latent/active TB) prior to initiation; for patients with TB disease or positive TB screening without a history of appropriate treatment, consult infectious disease specialist before initiating treatment. Assess ALT/AST and serum bilirubin prior to initiation; use with caution if ALT/AST &gt;1.5 times ULN.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="533b3d0e-6a18-4264-be77-ae9e03c9578d">Neuromyelitis optica spectrum disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromyelitis optica spectrum disorder: SubQ:</b> Loading dose: 120 mg once every 2 weeks for 3 doses (weeks 0, 2, and 4), followed by maintenance dose: 120 mg once every 4 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage for delayed or missed doses (reasons other than increased liver enzymes):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Missed loading dose: </i>120 mg as soon as possible (do not wait until next planned dose). If the second loading dose is delayed or missed, administer as soon as possible and administer the third (final) loading dose 2 weeks later. If the third loading dose is delayed or missed, administer as soon as possible and administer the first maintenance dose 4 weeks later.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Missed maintenance dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If &lt;8 weeks since last dose: 120 mg as soon as possible (do not wait until the next planned dose). Reset dose schedule to every 4 weeks after delayed or missed dose administered.</p>
<p style="text-indent:-2em;margin-left:6em;">If 8 to &lt;12 weeks since last dose: 120 mg every 2 weeks for 2 doses (weeks 0 and 2), followed by 120 mg every 4 weeks. <b>Note:</b> “Week 0” refers to time of the first administration after the missed dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If ≥12 weeks since last dose: 120 mg every 2 weeks for 3 doses (weeks 0, 2, and 4), followed by 120 mg every 4 weeks.<b> Note: </b>“Week 0” refers to time of the first administration after the missed dose.</p></div>
<div class="block dora drugH1Div" id="F54779732"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54779733"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in patients with baseline ALT/AST &gt;1.5 × ULN.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT/AST &gt;5 × ULN and any bilirubin elevation: Discontinue therapy; reinitiation not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT/AST &gt;5 × ULN and not associated with bilirubin elevation: Interrupt therapy until ALT/AST return to normal range, then restart as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">If &lt;12 weeks since last dose: Administer 120 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">If ≥12 weeks since last dose: Administer 120 mg every 2 weeks for 3 doses (weeks 0, 2, and 4) followed by 120 mg every 4 weeks. <b>Note:</b> “Week 0” refers to time of the first administration after the missed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Monitor LFTs closely and discontinue therapy without reinitiation if subsequent increases in ALT/AST and/or bilirubin above ULN occur.</p></div>
<div class="block dot drugH1Div" id="F54779734"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Decreased neutrophil count: Neutrophil count &lt;1,000/mm<sup>3</sup> (confirmed by repeat testing): Interrupt therapy until neutrophil count returns to &gt;1,000/mm<sup>3</sup>.</p></div>
<div class="block doe drugH1Div" id="F54779731"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F55632055"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Elevated liver enzymes</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate elevations in liver enzymes have occurred, including <b>increased serum alanine aminotransferase</b> (ALT) and <b>increased serum aspartate aminotransferase </b>with or without increased bilirubin<b>.</b> The majority of reported cases were transient and/or resolved without dose interruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797372'])">Ref</a></span>). May require dosage adjustment, treatment interruption, and/or treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Not well characterized; in 1 patient, elevations of ALT &gt;5 times the upper limit of normal were observed 4 weeks after initiation of therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decreased platelet counts</b> and <b>neutropenia</b> have occurred. The majority of reported cases were transient and/or resolved without dose interruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797372'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including anaphylaxis (fatal), <b>skin rash</b>, and urticaria, have occurred with other interleukin-6 (IL-6) receptor antagonists; anaphylaxis was not seen in satralizumab in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797372'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) receptor antagonists, including satralizumab, have immunosuppressive effects that are reversible with discontinuation. An increased risk of <b>infection</b> (including <b>severe infections</b> or potentially fatal infections) has been observed with satralizumab; an increased risk for <b>cellulitis</b>, <b>nasopharyngitis</b>, <b>upper respiratory tract infection</b>, and <b>pharyngitis </b>was noted in clinical trials<b>.</b> Clinicians should be aware of the potential for hepatitis B virus (HBV) reactivation or tuberculosis that exists with the use of immunosuppressant therapies, including IL-6 receptor antagonists.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; related to pharmacologic action (ie, immunosuppressive effects).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of active infection, including localized infections</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• Tuberculosis: </i>Preexisting tuberculosis risk factors; tuberculosis infection</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• HBV reactivation: </i>Chronic carriers of HBV [HBsAg+]; patients who are negative for HBsAg and positive for HB core antibody [HBcAb+]</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54756265"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling and without concurrent immunosuppressive therapy unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (17%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Skin Rash" frame="border" id="lexi-content-satralizumab-adverse-reaction-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (total cholesterol &gt;300 mg/dL: 12%), increased serum triglycerides (&gt;300 mg/dL: 27%), weight gain (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastritis (with concurrent immunosuppressant therapy: 15%), nausea (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count (26%; with concurrent immunosuppressant therapy: 35%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Decreased Platelet Count table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-decreased-platelet-count" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-decreased-platelet-count')">table 2</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Decreased Platelet Count</span>, neutropenia (10%; with concurrent immunosuppressant therapy: 15%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 3</a>)</span><span class="table-link" style="display:none;">Neutropenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Decreased Platelet Count" frame="border" id="lexi-content-satralizumab-adverse-reaction-decreased-platelet-count" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Decreased Platelet Count</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (43%; with concurrent immunosuppressant therapy: 8%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-increased-serum-alanine-aminotransferase')">table 4</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase</span>, increased serum aspartate aminotransferase (25%; with concurrent immunosuppressant therapy: 8%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-increased-serum-aspartate-aminotransferase')">table 5</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-satralizumab-adverse-reaction-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-satralizumab-adverse-reaction-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (73%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (54%; including severe infection: 10%) (Traboulsee 2020)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Infection table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-infection')">table 6</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Infection" frame="border" id="lexi-content-satralizumab-adverse-reaction-infection" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">63</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Traboulsee 2020</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">63</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Traboulsee 2020</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (15%), headache (with concurrent immunosuppressant therapy: 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (17%), limb pain (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (12%; with concurrent immunosuppressant therapy: 31%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Nasopharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-nasopharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-nasopharyngitis')">table 7</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Nasopharyngitis</span>, pharyngitis (with concurrent immunosuppressant therapy: 12%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Pharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-pharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-pharyngitis')">table 8</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Pharyngitis</span>, upper respiratory tract infection (with concurrent immunosuppressant therapy: 19%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-upper-respiratory-tract-infection')">table 9</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Nasopharyngitis" frame="border" id="lexi-content-satralizumab-adverse-reaction-nasopharyngitis" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Nasopharyngitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Pharyngitis" frame="border" id="lexi-content-satralizumab-adverse-reaction-pharyngitis" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Pharyngitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Upper Respiratory Tract Infection" frame="border" id="lexi-content-satralizumab-adverse-reaction-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">With concurrent immunosuppressant therapy</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (10%)<span class="lexi-table-link-container"> (<a aria-label="Satralizumab: Adverse Reaction: Cellulitis table link" class="lexi-table-link" data-table-id="lexi-content-satralizumab-adverse-reaction-cellulitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-satralizumab-adverse-reaction-cellulitis')">table 10</a>)</span><span class="table-link" style="display:none;">Satralizumab: Adverse Reaction: Cellulitis</span>, pruritus (10%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Satralizumab: Adverse Reaction: Cellulitis" frame="border" id="lexi-content-satralizumab-adverse-reaction-cellulitis" rules="all">
<caption style="text-align:center;">
<b>Satralizumab: Adverse Reaction: Cellulitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Satralizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including injection-site pruritus and residual mass at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (10%), falling (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased serum fibrinogen, disorder of hemostatic components of blood (reduction in C3 and C4 complement levels)</p></div>
<div class="block coi drugH1Div" id="F54749990"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to satralizumab or any component of the formulation; active hepatitis B infection; tuberculosis (TB) disease (active TB) or untreated TB infection (latent TB).</p></div>
<div class="block war drugH1Div" id="F54779719"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Immunization with live-attenuated or live vaccines is not recommended during therapy.</p></div>
<div class="block foc drugH1Div" id="F54809548"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enspryng: Satralizumab-mwge 120 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F54809546"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54868176"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Enspryng Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg/mL (per mL): $20,611.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54927894"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enspryng: Satralizumab-mwge 120 mg/mL (1 ea)</p></div>
<div class="block adm drugH1Div" id="F54779735"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SubQ:</b> Prior to use, remove prefilled syringe from refrigeration and carton and allow to sit at room temperature for 30 minutes; do not warm product in any other way. Administer the full amount in the prefilled syringe (1 mL). Administer subcutaneously into the abdomen or thigh. Rotate injection sites with each administration; avoid injecting into moles, scars, or tender, bruised, red, or hard skin. After proper training, patients may self-inject, or the patient's caregiver may administer satralizumab.</p></div>
<div class="block meg drugH1Div" id="F57290259"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Enspryng: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761149s005lbl.pdf%23page%3D16&amp;token=602Ltjq6EMDnxuqvi238%2Bj%2F3SaI6UsTpn9t1Icmp95IdF608pofddFbTWmFLYWYykzClvdiqwHI8qIJV%2BovSBLmv430mbyM%2B%2FybF0jv9IWfvF5ciXKpW%2FjPGpshphzUV&amp;TOPIC_ID=129293" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761149s005lbl.pdf#page=16</a></p></div>
<div class="block use drugH1Div" id="F54749989"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Neuromyelitis optica spectrum disorder:</b> Treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 (AQP4) antibody positive.</p></div>
<div class="block cyt drugH1Div" id="F54802894"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54802891"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline: Interleukin-6 (IL-6) Inhibiting Therapies may decrease the serum concentration of Theophylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F54779717"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Satralizumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal neuromyelitis optica spectrum disorder (NMOSD) may be associated with adverse pregnancy outcomes. Information related to the treatment of NMOSD in pregnancy is limited; agents other than satralizumab may be preferred (Borisow 2018; Chang 2020; Holmøy 2021; Kim 2020; Zhu 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to satralizumab is ongoing. Health care providers are encouraged to enroll patients exposed to satralizumab during pregnancy in the pregnancy exposure registry (1-833-277-9338); patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F54779718"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if satralizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Satralizumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F54779737"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hepatitis B virus screening (hepatitis B surface antigen [HBsAg] and hepatitis B core antibody [HBcAb] tests prior to therapy initiation); tuberculosis (TB) evaluation and risk factor assessment (prior to initiation), signs/symptoms of TB (throughout treatment); ALT/AST (prior to initiation, every 4 weeks for the first 3 months of treatment, then every 3 months for 1 year, and then as clinically warranted); serum bilirubin (prior to initiation and as clinically warranted); neutrophil counts (4 to 8 weeks after initiation and then at regular clinically determined intervals); signs/symptoms of any active infection (prior to each treatment).</p></div>
<div class="block pha drugH1Div" id="F54779723"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Satralizumab is an antagonist of the interleukin-6 (IL-6) receptor. Satralizumab is presumed to inhibit IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.</p></div>
<div class="block phk drugH1Div" id="F54779726"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Central V<sub>d</sub>: ~3.5 L; peripheral V<sub>d</sub>: ~2 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 85%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~30 days (range: 22 to 37 days).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522163"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Enspryng</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed</i>
<i>Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. <i>EPMA J</i>. 2018;9(3):249-256. doi:10.1007/s13167-018-0143-9</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31353503">
<a name="31353503"></a>Chang VTW, Chang HM. Review: recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. <i>Neuropathol Appl Neurobiol</i>. 2020;46(3):199-218. doi:10.1111/nan.12574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/31353503/pubmed" id="31353503" target="_blank">31353503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Enspryng (satralizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797372">
<a name="32797372"></a>Heo YA. Satralizumab: first approval. <i>Drugs</i>. 2020;80(14):1477-1482. doi:10.1007/s40265-020-01380-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/32797372/pubmed" id="32797372" target="_blank">32797372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33011853">
<a name="33011853"></a>Holmøy T, Høglund RA, Illes Z, Myhr KM, Torkildsen Ø. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. <i>J Neurol</i>. 2021;268(12):4522-4536. doi:10.1007/s00415-020-10235-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/33011853/pubmed" id="33011853" target="_blank">33011853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32320109">
<a name="32320109"></a>Kim SH, Huh SY, Jang H, et al. Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. <i>Eur J Neurol</i>. 2020;27(8):1546-1555. doi:10.1111/ene.14274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/32320109/pubmed" id="32320109" target="_blank">32320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32333898">
<a name="32333898"></a>Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurol</i>. 2020;19(5):402-412. doi:10.1016/S1474-4422(20)30078-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/32333898/pubmed" id="32333898" target="_blank">32333898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32533450">
<a name="32533450"></a>Zhu W, Zhang Y, Wang Z, Fu Y, Yan Y. Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside. <i>Neurosci Bull</i>. 2020;10.1007/s12264-020-00525-3. doi:10.1007/s12264-020-00525-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/satralizumab-drug-information/abstract-text/32533450/pubmed" id="32533450" target="_blank">32533450</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 129293 Version 76.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
